Key facts
- It has raised $1.5M.
- Notable investors include Creative Destruction Lab, ATEM Capital, InterSystems Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for PGxAI
- ·The full record, as it builds
Funding rounds
No funding rounds for PGxAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PGxAI
Developer of an artificial intelligence-powered platform designed for precision medicines utilizing pharmacogenetics. The company's platform uses advanced artificial intelligence and data analytics to support clinical decision-making and optimize patient outcomes, accelerate drug development, improve success rates and lower costs through targeted patient stratification and real-time analytics, deliver rapid, actionable reports through seamless LIMS integration, boosting precision and value for the clients, enabling healthcare organizations to implement personalized medicine on a large scale.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2023
- Employees
- 12
- Website
- pgx.ai/
- Ownership
- Privately Held (backing)
PGxAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PGxAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PGxAI in its N-PORT filings yet. We sweep new filings monthly.